Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Syndax Pharmaceuticals Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, ALSOMAIRY, SARAH ABDOALATIF, who also serves as the busiest examiner for the portfolio. All current prosecution activity is located within 1 distinct art unit. ALSOMAIRY, SARAH ABDOALATIF, is responsible for 1 busiest examiner pending action.
The concentration of the portfolio in 1 distinct art unit under 1 distinct examiner suggests a specific technical focus within Biotechnology & Pharmaceuticals. The busiest examiner is the sole point of contact for the company's current interactions with the patent office. This centralized structure can lead to a consistent prosecution path, as there are no competing examiner perspectives to reconcile. However, the progress of the entire pending portfolio is dependent on the review speed of this individual. Practitioners working on this portfolio deal with a unified set of art unit guidelines. The presence of 1 pending office action indicates a focused prosecution pipeline. This lack of examiner diversity means that the company's current legal strategy is entirely focused on the feedback from the examiner within the art unit. The alignment of the workload under ALSOMAIRY, SARAH ABDOALATIF, ensures that all technical arguments are reviewed by the same individual. For a practitioner, this means that building a rapport with the examiner is central, as there are no other active applications to offset a negative outcome here.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18666375 | METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18666375 | METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112DP | Non-Final OA | — | Pending | May 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSyndax Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarah Abdoalatif Alsomairy has the most, with 1 of Syndax Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
